Lung Cancer Antigen Expression Characterized by Molecular Subtype

Dec 9, 2021

Researchers discuss the use of cancer testis antigens as potential therapeutic targets for lung cancer, focusing on KK-LC-1 expression levels in different subtypes. They highlight the correlation between KK-LC-1 expression and histological subtypes, along with the association with increased tumor mutation burden. The chapter also delves into study limitations and the need for future research to establish targeted therapy thresholds for NSCLC.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 4min

Lung Cancer Antigen KKLC1 Expression in Different Subtypes and Mutation Burden

03:36 • 3min

Exploration of Study Limitations and Future Research Needs in Cancer Antigen Expression

06:42 • 1min

Lung cancer continues to be the leading cause of cancer deaths world-wide. Variations in the stage of diagnosis, subtypes and types of mutated genes provide a challenge for researchers who are developing targeted treatments to help rid patients of lung cancer. To this end, many researchers are interested in employing cancer-testis antigens (CTAs), which are minimally expressed in normal tissues, but strongly expressed in solid tumors. Therefore, CTAs are appealing therapeutic targets. The Kita-Kyushu lung cancer antigen-1 (also known as KK-LC-1; CT 83; CXORF61) is a CTA that is expressed in 82% of gastric tumors, 53% of breast cancers (higher in triple-negative breast cancer) and in about 33% of lung cancers. “In lung cancer, surgical series have shown KK-LC-1 to be expressed in about one-third of lung cancer tumors [1, 3–5].” Researchers—from the University of Southern California, Caris Life Sciences, Fox Chase Center, Georgetown Lombardi Comprehensive Cancer Center, The Warren Alpert Medical School of Brown University, Wayne State University School of Medicine, The Barbara Karmanos Cancer Institute, St. Marianna University, and the University of Utah—conducted a recent study to determine exactly which molecular subtypes of KK-LC-1 expressing lung cancer would be most responsive to a clinical trial involving the treatment of cancer with activated T lymphocytes from the body, or T cell receptor therapy (TCR-T), targeting KK-LC-1. Their research paper was published as cover of Oncotarget’s Volume 12, Issue 25, and entitled, “Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas”. Full blog - https://www.oncotarget.org/2021/12/08/lung-cancer-antigen-expression-characterized-by-molecular-subtype/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28132 DOI - https://doi.org/10.18632/oncotarget.28132 Full text - https://www.oncotarget.com/article/28132/text/ Correspondence to - Jorge J. Nieva - jorge.nieva@med.usc.edu Keywords - lung cancer, tumor microenvironment, diagnostic biomarkers, biomarkers for immunotherapy, cancer testis antigen About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957